Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence
Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu
Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu
View: Text | PDF
Research Article Cell biology Oncology

Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence

  • Text
  • PDF
Abstract

Chordomas are rare malignant osseous neoplasms with a striking rate of recurrence. Primary chordomas typically originate from embryonic notochord remnants, whereas recurrent chordomas usually stem from tumor cells infiltrating bone or cartilage after surgery. Clinically, the recurrent chordomas exhibit a stiffer extracellular microenvironment (ECM) than primary tumors. Intriguingly, this study identified cytoskeleton rearrangement, stress fiber reorganization, enhanced stemness, and Notch signaling activation in recurrent chordoma tissues or cell lines surviving stiff substrates, indicating the critical roles of mechanical remodeling and tumor stemness in stiffness resistance. We propose a potentially novel recurrence model where tumor cells experience mechanoadaptive organization, which enables them to resist stiff microenvironment-induced cell death. O-GlcNAcylation of Notch1 intracellular domain (NICD1) is central to this process. Mechanistically, the stiff ECM-driven ligand-independent phosphorylation of EPHA2 sequentially activated LYN kinase and subsequently triggered O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) activity by phosphorylating Y989 and Y418, critical residues for OGT glycosyltransferase activity; this induced NICD1 O-GlcNAcylation at T2063, T2090, and S2162, specifically promoting transcription of mechanical and stemness-related genes. MIR31 deletion upregulated LYN, enhancing stiffness perception and promoting O-GlcNAc addition to NICD1, finally resulting in mechanoadaptation- and tumor stemness–driven recurrence. Consequently, MIR31 deletion is a potential biomarker for recurrence and patient stratification in Notch- or OGT-targeted therapies.

Authors

Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu

×

Figure 3

NICD1 O-GlcNAcylation promotes tumor mechanical properties remodeling and tumor stemness.

Options: View larger image (or click on image) Download as PowerPoint
NICD1 O-GlcNAcylation promotes tumor mechanical properties remodeling an...
(A) Collagen-based cell contraction assay was used to assess cellular contractility and cell-ECM interactions for cells with PUGNAC, GlcNAc, and NICD1 overexpression. Whether the effect of pro–O-GlcNAc treatment could be abrogated by Notch inhibition was also assessed. (B) Phalloidin staining and IF were used to analyze F-actin and VCL expression. The colocalization areas indicate focal adhesions. Scale bar: 10 μm. (C) AFM was used to detect the stiffness of MUG-Chor1 cells. (D) IF was used to detect COL1A1, FN1, and NICD1 expression in spheroids harvested by performing sphere formation assay. Cells were cultured with PUGNAC (50 μM), GlcNAc (10 μM), or OSMI-1 (50 μM) for 7 days. Scale bar: 50 μm. (E) GSEA analysis was used to analyze the correlation between Notch activity and mechanical-related gene signature in patients with glioma from the TCGA dataset. (F) Protein levels of NICD1 O-GlcNAcylation, NICD1, and global O-GlcNAc were assessed by Duolink PLA and IHC. Expression of Notch signaling–, CSC-, and differentiation-related genes was determined using qRT-PCR (n = 10). Correlation was analyzed using the Pearson’s correlation coefficient. P values are listed in the boxes. (G and H) 1 × 107 MUG-Chor1 cells were inoculated subcutaneously. Tumors were treated with PUGNAC (10 mg/kg) and GlcNAc (10 mg/kg). After 6 weeks, tumors were treated with DAPT (1 mg/kg) or OSMI-1 (1 mg/kg) every 3 days. (G) Volume and weight of the subcutaneous tumors were detected (n = 5/group). (H) The effects of pro–O-GlcNAc treatment and OSMI-1 on extracellular proteoglycan level were determined by using AB/PAS staining. Red arrows show acid mucus, and green arrows show proteoglycan. Scale bar: 50 μm. (I and J) TUNEL assay in cells cultured with indicated treatment. Whether inhibiting cytoskeleton rearrangement could abrogate effects of NICD1 O-GlcNAcylation was analyzed by utilizing SMIFH2 (5 μM, 48 hours), which could inhibit actin polymerization. Data in A, C, G, I, and J are presented as mean ± SD. Statistical analysis was performed using 1-way ANOVA. *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts